Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEETINGS - Conference on The Investment in Innovation - In3 (US) February 2005:

This article was originally published in Clinica

Executive Summary

The Investment in Innovation - In3,conference is to be held by Medtech Insight in Irvine, California, on February 10-11 2005. The event will highlight emerging technologies, and is expected to draw up to 400 senior executives from the medical technology industry. For more details, contact Medtech Insight, 23 Corporate. Plaza, Suite 225, Newport Beach, California 92660, US. Tel: +1 714 964 6212; fax: +1 714 964 2332; email: delia@medtechinsight.com www.medtechinsight.com

You may also be interested in...



Sun, Accord, Amneal And Apotex Donate Hydroxychloroquine

Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.

Coronavirus Update: Inovio Begins Phase I Trials of DNA Vaccine, Fast-Track Drug Dialogue Continues

Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?

Switzerland Approves Raft Of Rx-To-OTC Switches

Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.

Topics

UsernamePublicRestriction

Register

MT060283

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel